Via Pharmaceuticals Net Income
| VIAP Stock | USD 0.0005 0.00 0.00% |
In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Via Pharmaceuticals, as well as the relationship between them.
Analyzing historical trends in various income statement and balance sheet accounts from Via Pharmaceuticals' financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Via Pharmaceuticals' valuation are summarized below:There are currently one hundred fifteen fundamental trend indicators for Via Pharmaceuticals that can be evaluated and compared over time across competition. Investors and active traders are advised to double-check Via Pharmaceuticals' current fundamental performance against the performance between 2010 and 2026 to make sure the trends are evolving in the right direction. As of 02/05/2026, Enterprise Value is likely to grow to about 13.9 M, while Market Cap is likely to drop slightly above 699.5 K. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -11 M | -11.6 M | |
| Net Loss | -11 M | -11.6 M | |
| Net Loss | -11 M | -11.6 M | |
| Net Loss | (0.42) | (0.44) |
Via | Net Income | Build AI portfolio with Via Stock |
Evaluating Via Pharmaceuticals's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Via Pharmaceuticals's fundamental strength.
Latest Via Pharmaceuticals' Net Income Growth Pattern
Below is the plot of the Net Income of Via Pharmaceuticals over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Via Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Via Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Via Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Via Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (9.6 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Via Net Income Regression Statistics
| Arithmetic Mean | (10,522,876) | |
| Coefficient Of Variation | (28.24) | |
| Mean Deviation | 1,517,865 | |
| Median | (9,601,315) | |
| Standard Deviation | 2,971,511 | |
| Sample Variance | 8.8T | |
| Range | 12.2M | |
| R-Value | 0.30 | |
| Mean Square Error | 8.6T | |
| R-Squared | 0.09 | |
| Significance | 0.24 | |
| Slope | 176,110 | |
| Total Sum of Squares | 141.3T |
Via Net Income History
Other Fundumenentals of Via Pharmaceuticals
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Via Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Via Pharmaceuticals is extremely important. It helps to project a fair market value of Via Stock properly, considering its historical fundamentals such as Net Income. Since Via Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Via Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Via Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Can Biotechnology industry sustain growth momentum? Does Via have expansion opportunities? Factors like these will boost the valuation of Via Pharmaceuticals. If investors know Via will grow in the future, the company's valuation will be higher. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Via Pharmaceuticals demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
The market value of Via Pharmaceuticals is measured differently than its book value, which is the value of Via that is recorded on the company's balance sheet. Investors also form their own opinion of Via Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Via Pharmaceuticals' true underlying value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Because Via Pharmaceuticals' market value can be influenced by many factors that don't directly affect Via Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Via Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Via Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Via Pharmaceuticals' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Via Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Via Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Via Pharmaceuticals.
| 11/07/2025 |
| 02/05/2026 |
If you would invest 0.00 in Via Pharmaceuticals on November 7, 2025 and sell it all today you would earn a total of 0.00 from holding Via Pharmaceuticals or generate 0.0% return on investment in Via Pharmaceuticals over 90 days. VIA Pharmaceuticals, Inc., a development stage biotechnology company, focuses on the development of compounds for the tr... More
Via Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Via Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Via Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
Via Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Via Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Via Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Via Pharmaceuticals historical prices to predict the future Via Pharmaceuticals' volatility.Via Pharmaceuticals Backtested Returns
We have found three technical indicators for Via Pharmaceuticals, which you can use to evaluate the volatility of the company. The entity has a beta of 0.0, which indicates not very significant fluctuations relative to the market. the returns on MARKET and Via Pharmaceuticals are completely uncorrelated.
Auto-correlation | 0.00 |
No correlation between past and present
Via Pharmaceuticals has no correlation between past and present. Overlapping area represents the amount of predictability between Via Pharmaceuticals time series from 7th of November 2025 to 22nd of December 2025 and 22nd of December 2025 to 5th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Via Pharmaceuticals price movement. The serial correlation of 0.0 indicates that just 0.0% of current Via Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.0 | |
| Spearman Rank Test | 1.0 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Via Operating Income
Operating Income |
|
Based on the recorded statements, Via Pharmaceuticals reported net income of (9.6 Million). This is 102.81% lower than that of the Biotechnology sector and 113.71% lower than that of the Health Care industry. The net income for all United States stocks is 101.68% higher than that of the company.
Via Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Via Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Via Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Via Pharmaceuticals by comparing valuation metrics of similar companies.Via Pharmaceuticals is currently under evaluation in net income category among its peers.
Via Fundamentals
| Return On Asset | -2.42 | ||||
| Current Valuation | 226.14 K | ||||
| Shares Outstanding | 20.56 M | ||||
| Number Of Shares Shorted | 10.27 K | ||||
| Price To Earning | (0.01) X | ||||
| Price To Book | 1.89 X | ||||
| EBITDA | (5.84 M) | ||||
| Net Income | (9.6 M) | ||||
| Cash And Equivalents | 84 K | ||||
| Total Debt | 14 M | ||||
| Current Ratio | 0.02 X | ||||
| Book Value Per Share | (0.90) X | ||||
| Cash Flow From Operations | (6.11 M) | ||||
| Short Ratio | 0.06 X | ||||
| Earnings Per Share | (0.01) X | ||||
| Target Price | 5.0 | ||||
| Beta | -0.62 | ||||
| Market Capitalization | 10.28 K | ||||
| Total Asset | 499.97 K | ||||
| Retained Earnings | (91.21 M) | ||||
| Working Capital | (18.55 M) | ||||
| Current Asset | 444 K | ||||
| Current Liabilities | 18.99 M | ||||
| Net Asset | 499.97 K |
About Via Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Via Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Via Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Via Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Via Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Via Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Via Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Via Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Via Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Via Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Via Pharmaceuticals to buy it.
The correlation of Via Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Via Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Via Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Via Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Via Stock Analysis
When running Via Pharmaceuticals' price analysis, check to measure Via Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Via Pharmaceuticals is operating at the current time. Most of Via Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Via Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Via Pharmaceuticals' price. Additionally, you may evaluate how the addition of Via Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.